IM/SC Childn 1-5 yr Single dose of 0.5 mL, 6-12 mth 2 doses of 0.5 mL administered 1 mth apart, followed by a booster inj (0.5 mL) at 18 mth of age, <6 mth 3 successive doses of 0.5 mL administered 1 or 2 mth apart, followed by a booster inj (0.5 mL) 1 yr after the 3rd inj.
View Act-HIB overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to any of the vaccine components, to tetanus protein, or to formaldehyde. Hypersensitivity following inj of vaccine containing same substances, or following prior inj of HIB conjugate vaccine. Postpone vaccination in case of fever or acute disease.
Do not inj intravascularly. Does not protect against infections due to other types of H. influenzae, or against meningitis of other origins. Tetanus protein in this vaccine cannot be used to replace the usual tetanus vaccination. Caution in patients w/ weakened immune system, or those treated w/ corticosteroids, cytotoxic drugs, RT or other immunosuppressants; patients w/ bleeding disorders (eg, thrombocytopenia) or clotting disorders; patients w/ latex hypersensitivity. Pregnancy & lactation.
Inj site reactions (eg, pain, redness, swelling &/or inflammation, induration); irritability. Uncontrollable or abnormal crying; fever; vomiting.
Drug Interactions
Administer at separate inj sites in case of concomitant administration w/ MMR vaccine or vaccines against diphtheria, tetanus, pertussis & poliomyelitis. +ve urine test for HIB capsular polysaccharide antigen can be observed w/in 1-2 wk following vaccination.
Sign Out
